Glenmark Pharmaceuticals Inc., USA has announced the launch of its Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial. This product is bioequivalent and therapeutically equivalent to the reference listed drug from BPI Labs, LLC. The market for Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) achieved annual sales of approximately $67.6 million (₹561.8 crore) for the 12-month period ending October 2025, according to IQVIA sales data. Marc Kikuchi, President & Business Head, North America, stated, "We are excited to announce the launch of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial, growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients." Glenmark Pharmaceuticals Limited is a research-led, global pharmaceutical company with a presence across Branded, Generics, and OTC segments, focusing on respiratory, dermatology, and oncology therapeutic areas. It operates 11 manufacturing facilities across 4 continents and in over 80 countries.